Last Updated : August 26, 2024
Details
FilesGeneric Name:
Pembrolizumab
Project Status:
Complete
Therapeutic Area:
Melanoma (Skin)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Sub Line:
Oncology Single Drug Reviews (Non-Sponsored)
Project Number:
PX0346-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Fee Schedule:
Pending
Indications:
Neoadjuvant treatment
of adult patients with Stage III or Stage IV melanoma
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | November 09, 2023 |
|---|---|
| Call for patient/clinician input closed | January 08, 2024 |
| Call for industry input open | November 09, 2023 |
| Call for industry input closed | January 08, 2024 |
| Submission received | October 24, 2023 |
Files
Last Updated : August 26, 2024